
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
On the Job-Where to Go for the Best Career Resources
Advice for Retirees Who Still Want to Play the Field
What to Consider When Considering Academia
The Benefits and Pitfalls of Private Practice
The Benefits and Pitfalls of Working in a Group Setting
Cases in Ethical Psychiatry: Should You Pray With Your Patient?
Thinking of Leaving Clinical Practice? You're Not Alone!




